Abstract 1189: Establishment of patient-derived xenograft (PDX) models for small cell lung cancer (SCLC) as a preclinical platform for drug development

Abstract

Abstract Small cell lung cancer comprises 15-20% of all lung cancer cases, and is more invasive and has a higher rate of proliferation with respect to non-small cell lung cancer, leading to a higher mortality rate. Most cases are responsive to chemotherapy, however there is a high rate of recurrence with treated patients and those in advanced stage of the disease often have a refractory response to treatment. As such, the need for new treatment modalities is critical. Use of patient-derived tumor xenograft (PDX) models as clinically-relevant preclinical model for novel drug development has gained widespread adoption in recent years. In previous work, we have reported using the Molecular Response tumor bank, comprising >144,000 viable tumor specimens, to establish more than 100 PDX models of various cancer types. In this work, we describe the development of 8 new SCLC PDX models established from a collection of >300 small cell lung cancer specimens, many of which come from prior-treated and metastatic patients. We report a comprehensive characterization of these models, including: histopathology, immunohistochemistry, and mutation analysis by next-generation sequencing. Additionally, we have evaluated functional response of these models with in vivo pharmacology studies. Current studies are underway to derive correlations between in vivo drug response and mutational status of these models. Our data strongly suggests the potential to use these unique PDX models to aid in efforts in drug development efforts in oncology. Citation Format: Patrick Carlson, Jill Ricono, Chelsea Mullins, Thomas Broudy, Cyrus Mirsaidi, Praveen Nair. Establishment of patient-derived xenograft (PDX) models for small cell lung cancer (SCLC) as a preclinical platform for drug development. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1189. doi:10.1158/1538-7445.AM2014-1189